Search
forLearn
5 / 801 resultslearn TDM-105795
learn copper tripeptide-1
learn microbiota modulator
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 50 results
research Cystathionine β‐synthase‐deficient mice thrive on a low‐methionine diet
Mice with CBS deficiency are healthier on a low-methionine diet.
research Congenital ptosis repair with a frontalis silicon sling: comparison between Fox's single pentagon technique and a modified Crawford double triangle technique
The modified Crawford technique resulted in less lagophthalmos and better cosmetic outcomes for patients with lateral droop.
research The Relationship Between Eyebrow and Eyelid Position in Patients With Ptosis, Dermatochalasis and Controls
In ptosis, brow elevation doesn't lift the eyelid but is driven by efforts to raise the eyelid.
research Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse
Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.
research Experimental and computational approaches for measuring minoxidil solubility in propylene glycol + water mixtures at different temperatures
Minoxidil dissolves better in propylene glycol and water as temperature and propylene glycol amount increase.
Community Join
5 / 1000+ resultscommunity MCL1 does anyone knows anthying about it
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community How’s RCH-01 doing?
RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.